APM
NASDAQAptorum Group Limited
Price$7.08-1.67 (-19.14%)
2026-04-142026-07-17
News · 26 weeks29-29%
2026-03-012026-08-23
Mix1890d
- SEC Filings8(44%)
- Other5(28%)
- Insider5(28%)
Latest news
25 items- SECAmendment: Aptorum Group Limited filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Niki BioSolutions, Inc. (0001734005) (Filer)
- SECAptorum Group Limited filed SEC Form 8-K: Financial Statements and Exhibits8-K - Niki BioSolutions, Inc. (0001734005) (Filer)
- INSIDERNew insider Arner Douglas Wayne claimed ownership of 1,062 shares (SEC Form 3)3 - Niki BioSolutions, Inc. (0001734005) (Issuer)
- INSIDERNew insider Wu Justin Che Yuen claimed ownership of 1,832 shares (SEC Form 3)3 - Niki BioSolutions, Inc. (0001734005) (Issuer)
- SECAptorum Group Limited filed SEC Form 8-K: Other Events8-K - Niki BioSolutions, Inc. (0001734005) (Filer)
- INSIDERSEC Form 3 filed by new insider Mireskandari Alidad3 - Niki BioSolutions, Inc. (0001734005) (Issuer)
- SECSEC Form SCHEDULE 13D filed by Aptorum Group LimitedSCHEDULE 13D - Niki BioSolutions, Inc. (0001734005) (Subject)
- INSIDERNew insider Philips Laura A claimed ownership of 6,024 shares (SEC Form 3)3 - Niki BioSolutions, Inc. (0001734005) (Issuer)
- INSIDERNew insider Sheinerman Kira claimed ownership of 1,515,293 shares (SEC Form 3)3 - Niki BioSolutions, Inc. (0001734005) (Issuer)
- SECAptorum Group Limited filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Niki BioSolutions, Inc. (0001734005) (Filer)
- PRAptorum Group Provides Update on DiamiR Biosciences MergerPost-Merger company, Niki BioSolutions, Inc., to Trade on Nasdaq Under Ticker "NIKI" Aptorum Group Announces 1-for-10 Reverse Share Split and Delaware Redomestication in Connection with the Merger The Merger is Expected to Close in July 2026 NEW YORK, NY, July 16, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited, a Cayman Islands exempted company with limited liability (NASDAQ:APM) ("Aptorum Group" or "Aptorum" or "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that the closing of its merger with DiamiR Biosciences Corp. ("Merger") is anticipated to take place on or about July 20, 2026. DiamiR Biosciences Corp. is a dev
- PRAptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International ConferenceNEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer’s Association International Conference (AAIC), taking place at the Excel London Convention & Exhibition Centre, in London, UK, and online, on July 11-15, 2026, showcasing biomarker technologies from DiamiR’s CLIA-certified, CAP-accredited clinical laboratory. Alidad Mir
- SECAmendment: SEC Form 6-K/A filed by Aptorum Group Limited6-K/A - Aptorum Group Ltd (0001734005) (Filer)
- PRAptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease BiomarkersNEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs. and DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a collaboration between DiamiR and AlzLabs Precision Diagnostics ("AlzLabs") to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer’s disease. "We are excited to collaborate with the AlzLabs team on this study to measure blood biomarkers of neurodegeneration, such as p-Tau 217
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- PRAptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR BiosciencesNEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced that at its shareholder meeting held on June 9, 2026, its shareholders voted to approve the proposed merger transaction with DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases. The approval by Aptorum Group's shareholders represents a significant milestone toward completing the previously announced all-stock merger transaction, pursuant to which DiamiR will become a wholly owned subsidiary of Aptorum Group. Diam
- SECSEC Form 424B3 filed by Aptorum Group Limited424B3 - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form EFFECT filed by Aptorum Group LimitedEFFECT - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form EFFECT filed by Aptorum Group LimitedEFFECT - Aptorum Group Ltd (0001734005) (Filer)
- SECAmendment: SEC Form S-4/A filed by Aptorum Group LimitedS-4/A - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form 6-K filed by Aptorum Group Limited6-K - Aptorum Group Ltd (0001734005) (Filer)
- SECAmendment: SEC Form S-4/A filed by Aptorum Group LimitedS-4/A - Aptorum Group Ltd (0001734005) (Filer)
- SECSEC Form 20-F filed by Aptorum Group Limited20-F - Aptorum Group Ltd (0001734005) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Aptorum Group Limited6-K/A - Aptorum Group Ltd (0001734005) (Filer)
APM FAQ
6 questionsWhat does Aptorum Group Limited do?
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it...Where does APM stock trade?
Aptorum Group Limited (APM) is listed on NASDAQ.What sector and industry is APM in?
Aptorum Group Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aptorum Group Limited go public?
Aptorum Group Limited (APM) completed its IPO in 2018.What companies are similar to APM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare APM side-by-side with any of them on Quantisnow.How can I track APM on Quantisnow?
Quantisnow aggregates Aptorum Group Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APM to receive live email and push alerts on every new disclosure.